I Ríos1,2, A Rovirosa3, C Ascaso4, I Valduvieco3, A Herreros3, L Castilla3, S Sabater5, K Holub3, J Pahisa6, A Biete3, M Arenas7. 1. Radiation Oncology Department, ICMHO, Functional Gynecologic Cancer Unit, Hospital Clinic Universitari, C/Villarroel no. 170, 08036, Barcelona, Spain. ivanriosh@gmail.com. 2. Radiation Oncology Department, Cancer Institute, Centro Medico Imbanaco, Cali, Colombia. ivanriosh@gmail.com. 3. Radiation Oncology Department, ICMHO, Functional Gynecologic Cancer Unit, Hospital Clinic Universitari, C/Villarroel no. 170, 08036, Barcelona, Spain. 4. Public and Health Department, Medicine Faculty, Universitat de Barcelona, Barcelona, Spain. 5. Radiation Oncology Department, Hospital General de Albacete, Albacete, Spain. 6. Gynecological Surgery, Functional Gynecologic Cancer Unit, Hospital Clinic I Universitari, Barcelona, Spain. 7. Radiation Oncology Department, Hospital Sant Joan de Reus, Tarragona, Spain.
Abstract
PURPOSE: To analyze the vaginal-cuff local control (VCC) and toxicity in postoperative endometrial carcinoma patients (EC) underwent high-dose-rate brachytherapy (HDR-BT) administered daily. MATERIALS AND METHODS: 154 consecutive patients received postoperative HDR-BT for EC from January 2007 to September 2011. FIGO-staging I-IIIC2 patients were divided into two groups according to risk classification: Group 1 (94/154) included high-risk or advanced disease patients and Group 2 (60/154) included intermediate-risk EC patients. Group 1 underwent external beam irradiation (EBI) plus HDR-BT (2 fractions of 5 Gy) and Group 2 underwent HDR-BT alone (4 fractions of 5 Gy). Toxicity evaluation was done with RTOG scores for bladder and rectum, and the objective criteria of LENT-SOMA for vagina. RESULTS: With a median follow-up of 46.7 months (36.6-61 months) only two patients developed vaginal-cuff recurrence in Group 1 (2.1 %) and none in group 2 (0 %). Early toxicity in Group 1 appeared 5.3 % in rectum, 7.5 % in bladder (G1-G2) and 2.1 % in vagina (G1); late toxicity was present in 7.3 % in rectum (all G1-G2 but 1 G3) and in 27.7 % in vagina (all G1-G2 but one G4). In Group 2, 6.7 % developed acute G1-G2 bladder and 6.6 % acute vaginal (G1-G2) toxicity. No late rectal or bladder toxicity was observed; 21.7 % of G1-G2 presented late problems in vagina. CONCLUSIONS: The present HDR-BT schedule of 2 fractions of 5 Gy after EBI and 4 fractions of 5 Gy administered daily showed excellent results in terms of VCC and toxicity.
PURPOSE: To analyze the vaginal-cuff local control (VCC) and toxicity in postoperative endometrial carcinomapatients (EC) underwent high-dose-rate brachytherapy (HDR-BT) administered daily. MATERIALS AND METHODS: 154 consecutive patients received postoperative HDR-BT for EC from January 2007 to September 2011. FIGO-staging I-IIIC2 patients were divided into two groups according to risk classification: Group 1 (94/154) included high-risk or advanced diseasepatients and Group 2 (60/154) included intermediate-risk EC patients. Group 1 underwent external beam irradiation (EBI) plus HDR-BT (2 fractions of 5 Gy) and Group 2 underwent HDR-BT alone (4 fractions of 5 Gy). Toxicity evaluation was done with RTOG scores for bladder and rectum, and the objective criteria of LENT-SOMA for vagina. RESULTS: With a median follow-up of 46.7 months (36.6-61 months) only two patients developed vaginal-cuff recurrence in Group 1 (2.1 %) and none in group 2 (0 %). Early toxicity in Group 1 appeared 5.3 % in rectum, 7.5 % in bladder (G1-G2) and 2.1 % in vagina (G1); late toxicity was present in 7.3 % in rectum (all G1-G2 but 1 G3) and in 27.7 % in vagina (all G1-G2 but one G4). In Group 2, 6.7 % developed acute G1-G2 bladder and 6.6 % acute vaginal (G1-G2) toxicity. No late rectal or bladder toxicity was observed; 21.7 % of G1-G2 presented late problems in vagina. CONCLUSIONS: The present HDR-BT schedule of 2 fractions of 5 Gy after EBI and 4 fractions of 5 Gy administered daily showed excellent results in terms of VCC and toxicity.
Authors: William Small; Sushil Beriwal; D Jeffrey Demanes; Kathryn E Dusenbery; Patricia Eifel; Beth Erickson; Ellen Jones; Jason J Rownd; Jennifer F De Los Santos; Akila N Viswanathan; David Gaffney Journal: Brachytherapy Date: 2012 Jan-Feb Impact factor: 2.362
Authors: Lua Eiriksson; Julie Cuartero; Helen Steed; Robert Pearcey; Valerie Capstick; Alexandra Schepansky; Wylam Faught; George Dundas Journal: Int J Gynecol Cancer Date: 2010-11 Impact factor: 3.437
Authors: J L Guinot; J Pérez-Calatayud; J M Azcoaga; I Herruzo; C Bodineau; A Rovirosa; V Crispín; P Galán; E González-Patiño; J Pérez-Regadera; A Polo Journal: Clin Transl Oncol Date: 2012-04 Impact factor: 3.405
Authors: Angeles Rovirosa; Carlos Ascaso; Alberto Sánchez-Reyes; Antonio Herreros; Rosa Abellana; Jaume Pahisa; Jose Antonio Lejarcegui; Albert Biete Journal: Int J Radiat Oncol Biol Phys Date: 2010-08-26 Impact factor: 7.038
Authors: I Valduvieco; Á Rovirosa; A Herreros; I Romera; I Ríos; C Ascaso; A Sánchez-Reyes; M Arenas; J Pahisa; A Biete Journal: Clin Transl Oncol Date: 2012-12-21 Impact factor: 3.405
Authors: Paweł Cisek; Dariusz Kieszko; Izabela Kordzińska-Cisek; Elżbieta Kutarska; Ludmiła Grzybowska-Szatkowska Journal: Biomed Res Int Date: 2018-02-21 Impact factor: 3.411
Authors: Jessica D Arden; Jonathan Dokter; Muayad F Almahariq; Kimberly Marvin; Sirisha R Nandalur; Zaid Al-Wahab; Jill Gadzinski; Barry Rosen; Maha Saada Jawad Journal: Adv Radiat Oncol Date: 2021-08-12
Authors: Yaowen Zhang; Carlos Ascaso; Antonio Herreros; Joan Sánchez; Sebastia Sabater; Marta Del Pino; Yan Li; Gabriela Gómez; Aureli Torné; Albert Biete; Ángeles Rovirosa Journal: Rep Pract Oncol Radiother Date: 2020-01-14
Authors: María Del Valle Aguilera; Ángeles Rovirosa; Carlos Ascaso; Antonio Herreros; Joan Sánchez; Julia Garcia-Migue; Stephanía Cortes; Eduardo Agusti; Cristina Camacho; Yaowen Zhang; Yan Li; Sebastià Sabater; Aureli Torne; Meritxell Arenas Journal: J Contemp Brachytherapy Date: 2018-02-28